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Post-operative nausea and vomiting (PONV) is defined as the occurrence of nausea,  
vomiting or retching after a surgical procedure either in post anesthesia care unit or  
within 24 hours after surgery. Post-operative nausea and vomiting , the second leading  
problem faced in the post anesthesia care unit, can affect 30 -80% of surgical patients  
based on patient-specific and anesthetic specific risk factors. There are several  
medications used routinely to prevent and/ or reduce the incidence of PONV.  The  
purpose of this systematic review was to investigate the efficacy of propofol compared to  
midazolam on reducing the incidence of PONV in the adult population after general  
anesthesia.  A database search was conducted using inclusion and exclusion criteria to  
select pertinent research articles from 2009 to 2019.   The PRISMA framework was  
utilized to guide the review and assist with article selection.  Then, the CASP checklist  
guided the appraisal of each article included in the review.   Data collection tables were  
created, and a cross-study analysis was conducted to explore the results of each article.   
Studies showed that both propofol and midazolam have anti-emetic properties  
even though the mechanisms of action are not truly understood.  Overall, propofol and  
midazolam alone or in combination with other anti-emetics showed significant reduction  
in PONV and rescue anti-emetic requirement.  By incorporating the use of propofol or  
midazolam into the anesthetic plan,  anesthesia providers will be able reduce the  
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Propofol Versus Midazolam on Reducing the Incidence of Post-Operative Nausea and 
Vomiting: A Systematic Review 
Background/Statement of the Problem 
 Post-operative nausea and vomiting (PONV) is defined as the occurrence of  
nausea, vomiting or retching after a surgical procedure either in the post-anesthesia care  
unit (PACU) or within 24 hours after surgery (Horn, Wallisch, Homantics & Williams,  
2013).  PONV, the second leading problem faced in the PACU, can affect 30 -80% of  
surgical patients based on patient-specific and anesthetic specific risk factors (Nagelhout  
& Elisha, 2018).  The risk factors that increase the incidence of PONV include female  
gender, non-smoker, history of PONV, history of motion sickness, and age less than 50  
years old.  Anesthetic related factors include use of volatile gases, use of nitrous oxide,  
duration of the surgery, and post-operative opioid use.  According to Shaikh, Nagarekha,  
Hegade & Marutheesh (2016), the type and length of surgery contributes to the risk as  
well.  The Society for Ambulatory Anesthesia (SAMBA),  a multidisciplinary panel of  
professionals, have implemented evidence-based guidelines and recommendations for use  
of antiemetic prophylaxis and treatment for post-operative nausea and vomiting  
(Nagelhout & Elisha, 2018).    The guidelines identify risk factors, suggest strategies for  
reducing PONV, identify effective therapies for prophylactically treating PONV  
(monotherapy and multimodal), and recommend treatment for active PONV (Gan et al.,  
2007).   SAMBA further implemented an algorithm for the management PONV for at- 
risk individuals (Gan et al., 2007).  
Post-operative nausea and vomiting (PONV) contributes to unfavorable  
consequences like delayed recovery, aspiration, hospital admission or increased length of  
stay, wound dehiscence and dehydration (Shaikh et al., 2016).  For many decades, PONV  
has been a problem for surgical patients due to its complex mechanism (Gibbison &  
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Spencer, 2009).  Extensive research has been conducted involving the effects of general  
anesthesia on the incidence of post-operative nausea and vomiting.  Prevention and  
treatment of PONV involves a multimodal approach (Nagelhout, 2018).    
Propofol, a short acting intravenous anesthetic, decreases the level of  
consciousness and results in lack of memory of medical events.  This medication has  
proven to decrease the incidence of PONV in surgical patients receiving general  
anesthesia.  General anesthesia can be delivered via total intravenous anesthesia, using  
volatile inhalation agents or a combination of both (Nagelhout & Elisha, 2018).  The  
largest challenge with general anesthesia is determining the best anesthetic plan for each  
patient to reduce or prevent post-operative nausea and vomiting. 
 Midazolam, a benzodiazepine, is commonly used in anesthesia as a sedative,  
anxiolytic, amnestic, and hypnotic drug (Nagelhout, 2018).  According to Samimi Sade,  
 Davari Tanha & Sadeghi (2010), the anti-emetic properties of midazolam are not  
completely understood but presumed to act at the chemoreceptor trigger zone (CRTZ).   
 The purpose of this systematic review was to investigate the efficacy of propofol  
compared to midazolam on reducing the incidence of post-operative nausea and vomiting  
in the adult population after general anesthesia. 




 A review of literature was performed to investigate the efficacy of propofol  
compared to  midazolam at reducing the incidence of post-operative nausea and vomiting  
in the adult population after general anesthesia.  Research articles were obtained by  
conducting a through database search on CINAHL, Medline, PubMed, and Google  
Scholar.  The search terms included general anesthesia, general anesthesia side effects,  
post-operative nausea and vomiting, propofol, midazolam, PONV prevention,  
prophylaxis treatment of post-operative nausea and vomiting, and anti-emetics.  Random  
control trials,  meta-analyses, and prospective cohort studies from 2009 to 2019 were  
included in the literature review. 
Post-operative Nausea and Vomiting 
Post-operative nausea and vomiting is defined as the occurrence of nausea,  
vomiting or retching after a surgical procedure either in PACU or within 24 hours after 
surgery (Horn, Wallisch, Homantics & Williams, 2014).  PONV, the second leading  
problem faced in the post-anesthesia care unit, can affect 30 -80% of surgical patients  
based on patient-specific and anesthetic specific risk factors (Abdelhamid &  
Kamel,2014).  According to Horn et al. (2014), patients reported that PONV is the most  
distressing adverse effect of anesthesia.   The “vomiting center” (VC) in the medulla  
oblongata is comprised of the reticular formation, a network of nuclei clusters and the  
chemoreceptor trigger zone (CTZ) (Hall, 2011). The VC connects to the nucleus tractus  
solitarius (NTS) that receives input from cardiovascular, respiratory, genital, and  
digestive organs (Becker, 2010). The VC  is activated by receiving many signals from  
sensory nerves in the gastrointestinal tract (peripheral pathways), the CTZ, cerebral  
cortex, and vestibular system (Moon, 2014).  Stimulation to the forebrain pathway causes  
nausea and stimulation of the hindbrain pathway results in coordinated parasympathetic  
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and efferent nerve responses to produce vomiting (Moon, 2014). The CTZ consists of  
receptors for dopamine, serotonin, acetylcholine, opioids, and substance P  The zone is  
located outside of the blood brain barrier, therefore, this area of the brain is susceptible to  
stimulation from medications, toxins, and metabolites triggering vomiting (Becker,   
2010).   
The American Society of Anesthesiologists (ASA) created a classification system  
to access a patient’s physical status prior to surgery (Abouleish, Leib, & Cohen, 2015).    
There are six categories ranging from a healthy individual without systemic disease to an  
individual that is declared brain-dead and/ or an organ donation candidate. Class I  
represents a healthy individual with no past medical history and class II involves some  
type of past medical history, prescribed medication or controlled systemic disease  
process.  
The study by Joe, Lee, Kim, Chang, Jeong, Jeong, & Park (2016) consisted of 72  
adult women with an ASA I or II that were randomly divided into the sevoflurane  
(volatile anesthetic gas) group or total intravenous anesthesia group using propofol. A  
nausea severity scale was used for evaluation purposes.  The collected data included the  
incidence of post-operative nausea and vomiting, nausea, and vomiting in early (0-6  
hours), late (6-24 hours), and overall (0-24 hours) and pain scores.   
The study showed the use of both intravenous propofol and a rescue anti- 
emetic, ramosetron, a serotonin type 3 receptor antagonist (5-HT₃),  had significant  
reduction on the incidence of  PONV compared to the sevoflurane (volatile anesthetic  
gas) group.  The incidence of  PONV in the early post-operative period in the total  
intravenous anesthesia group was 4 (11.1%) compared to the Sevoflurane group which  
was 20 (55.6%) with a P< 0.001 (Joe et al., 2016).  In the late period (6-24 hours), PONV  
in the intravenous propofol group was 6 (16.7%) compared to 11 (30.6%) and the overall  
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incidence of PONV was 7 (19.4%) compared to 22 (61.1%) with P=0.001 (P< 0.05  
considered statistically significant) (Joe et al., 2016).  The study suggested TIVA with  
propofol effectively reduces the incidence of PONV compared to using volatile gases  
such as sevoflurane.   
Risk Factors for Post-operative Nausea and Vomiting 
The patient-related risk factors of PONV include female gender, non-smoker,  
history of PONV, history of motion sickness, and age less than 50 years old.  Anesthetic  
related factors include use of volatile gases, use of nitrous oxide, duration and type of the  
surgery, and post-operative opioid use (Moon,2014).  Risk of PONV may be quantified  
by using the Apfel scoring system  consisting of four factors.  The Apfel score ranges  
from 0-4, predicting the percentage of PONV risk in the first 24 hours post-operatively. 
Öbrink, Jidenstål, Oddby & Jakobsson (2015) suggested that providing opioid  
free anesthesia is effective at reducing the incidence of post-operative nausea (68% vs.  
27%) and vomiting ( 32% vs 8%).  Horn et al. (2014) suggested that increased duration of  
surgery, tissue trauma, and inflammation contribute to the incidence of PONV.   
According to Pierre & Whelan (2013), dose dependent opioid use intraoperatively  
and post-operatively increased the risk of PONV.  “Opioids reduce muscle tone and  
peristaltic activity, thereby delaying gastric emptying, inducing distention, and triggering  
the vomiting reflex” (Pierre & Whelan, 2013, pg. 29). The most common procedures that  
increase the incidence of PONV include abdominal, orthopedic, gynecologic, and middle  
ear surgeries (Arcangelo & Peterson, 2013).  PONV contributes to unfavorable  
consequences like delayed recovery, aspiration, hospital admission or increased length of  
stay, wound dehiscence and dehydration (Shaikh et al., 2016).   
In 2015, the study by Naghibi, Kashefi, Azarnoush & Zabihi consisted of 104  
adult subjects with an ASA status of I or II that underwent lower abdominal surgery  
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electively.  The subjects were randomly divided into one of the four groups, the control,  
20mg propofol, 30mg propofol, or the 10mg metoclopramide group (Naghibi et al.,  
2015).  Naghibi et al. (2015) revealed in the first six hours following surgery both  
propofol groups showed decreased incidence of PONV with 23.08% and 15.38% in  
group 1 and 2 respectively developing PONV.   The study further suggested that the  
propofol 30 mg group and the metoclopramide 10 mg group were comparable at  
decreasing the incidence of PONV compared to the control group developing  
PONV (Naghibi et al., 2015). 
  Obtaining a complete pre-anesthesia assessment is crucial to prevent and   
reduce the incidence of post-operative nausea and vomiting (Arcangelo & Peterson,  
2013).  Reviewing the patient’s chart and interviewing the patient on day of surgery can  
potentially alert the advanced practice provider to any risk factors for developing PONV.   
Pharmacological Therapies  
The main objective is prevention and reduction of the incidence of PONV to  
improve patient satisfaction and potentially reduce health care costs related to untoward  
effects of anesthesia.  Anti-emetic preventative medications consist of serotonin  
antagonists, antihistamines-anticholinergics, corticosteroids, phenothiazines,  
butyrophenones, benzodiazepines, propofol, and the more recent neurokinin 1  
antagonists (Shaikh et al., 2016). The most common anti-emetics used in the operative  
setting consist of serotonin antagonists (5HT₃), corticosteroids, dopamine receptor  
antagonists, antihistamine-anticholinergics, and more recently propofol and benzo- 
diazepines (Moon, 2014).  According to Shaikh et al. (2016), PONV is a multifactorial  
adverse effect of general anesthesia and effective treatment involves a multimodal  




Serotonin antagonists.  
Serotonin receptor antagonists (5HT₃) are used as preventative and rescue   
treatment for PONV in the post-operative acute care unit (PACU) (Horn et al., 2014).   
This class of medication involves antagonism of both peripheral and central afferent  
receptors that cause nausea and vomiting (Horn et al., 2014).  Ondansetron (Zofran) is the 
anti-emetic commonly used in the peri-operative setting.  Typical dosing of Zofran  
consists of 4mg intravenous dose given either after induction of anesthesia or towards the  
end of the surgery.  The adverse effects include headache, abdominal pain, malaise,  
increased liver enzymes, and  potential prolongation of the QT interval (Arcangelo &  
Peterson, 2013).  
Corticosteroids.  
Corticosteroids or steroid hormones are produced in the adrenal cortex and are  
involved in several processes throughout the body such as stress response, inflammation,  
immune response, metabolism of carbohydrates and synthesis of proteins (Nagelhout &  
Elisha, 2018).   Steroid hormones are classified as glucocorticoids or mineralocorticoids.   
Glucocorticoids are anti-inflammatory, immunosuppressive, vasoconstrictive, and  
proliferative and mineralocorticoids regulate electrolyte and fluid balance (Nagelhout &  
Elisha, 2018). Dexamethasone, the commonly used synthetic corticosteroid is  
almost like pure glucocorticoids found in the adrenal cortex (Ho, Wu, Ho, & Wang,  
2011).  In the intra-operative setting, dexamethasone is used in conjunction with  
ondansetron to prevent PONV after general anesthesia however, the mechanism of action  
for dexamethasone remains unclear (Ho et al., 2011).  Even though corticosteroids have  
adverse effects with long term use, a single anti-emetic dose is relatively safe though  
contraindicated in diabetics unless benefit outweighs the risk (Nagelhout & Elisha, 2018).  
The randomized control study by Heidari, Talakoub & Yaraghi (2012), consisted  
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of 66 subjects undergoing elective middle ear surgery.  The study compared the effects 
of midazolam and midazolam-dexamethasone on the prevention of PONV.  The subjects 
were divided into two groups: midazolam (M) group that received 0.075mg/kg and the 
midazolam/ dexamethasone (M+D) group that received 0.075mg/kg of midazolam plus  
0.05 mg/kg of dexamethasone after induction.  Nausea severity was measured in PACU  
at time intervals of 6, 12, and 24 hours after surgery using the visual analog scale (0-10).  
The rescue anti-emetic used was metoclopramide 0.1 mg/kg if the VAS score was above  
3 or vomiting was present.  This data was collected along with the length of stay in  
PACU.  The study revealed less vomiting frequency in the combination group in PACU  
(0 ± 0), 6-12 h (0.3± 0.8), and 12-24h (0.03 ± 0.17) and reduced rescue anti-emetic  
requirements in the first 24 hours post-surgery in the combination group (P < 0.05). The  
study suggested the use of both midazolam and dexamethasone to effectively prevent  
PONV compared to midazolam alone. 
Antihistamines-anticholinergics.  
Antihistamines-anticholinergics are two classes of medication that include agents  
used for mild nausea and motion sickness however, scopolamine has been used  
cautiously in the operative setting due to post-operative delirium in the older population.   
“Scopolamine is a competitive inhibitor at postganglionic muscarinic receptors in the  
parasympathetic nervous system and acts directly on the central nervous system by  
antagonizing cholinergic transmission in the vestibular nuclei” (Horn et al., 2014, pg. 8).  
The mechanism of action involves the visceral sensory pathways that contribute to nausea  
and vomiting (Arcangelo & Peterson, 2013).  The scopolamine patch is used for surgical  
patients with a history of severe motion sickness (Horn et al., 2014).   
Dopamine antagonists.   
According to Moon (2014), dopamine receptors, mainly D₂ and D₃, are shown to  
9 
 
induce nausea and vomiting by reducing cAMP in the vomiting center of the brain  
(Moon, 2014).  Of the dopamine antagonists, metoclopramide (Reglan) and droperidol  
are the common medications used as part of a multimodal approach in preventing and  
treating post-operative nausea and vomiting (Nagelhout & Elisha, 2018).  Droperidol is a  
selective dopamine D₂ receptor antagonist.  Horn et al. (2014) suggested that droperidol  
is as effective as dexamethasone or ondansetron at preventing PONV.  The most common  
side effects include restlessness, minimal effect on sedation, QT prolongation, and  
ventricular arrhythmias (Horn et al., 2014).  According to Gan (2004), cases of QT  
prolongation and/or torsade de pointes have been reported, therefore the FDA suggested  
droperidol be used with caution and reserved for use when other anti-emetics fail (Gan,  
2004 ).   FDA further suggested the use of droperidol was contraindicated for patients  
with known or suspected QT prolongation, including patients with congenital long QT  
syndrome (FDA, 2020) . Metoclopramide, a potent D₂ receptor antagonist, also blocks 
H₁  
and 5-HT₃ receptors that enhances gastrointestinal motility, leading to an anti-emetic  
effect (Moon, 2014).    
Honarmand, Safavi, Khalili, & Mohammadnejad (2012) conducted a randomized,  
double-blind, placebo-controlled study consisting of 80 adult subjects scheduled for  
middle ear surgery under general anesthesia.  The subjects were randomly allocated into  
one of four groups: control (C), midazolam (M), haloperidol (H), or haloperidol plus  
midazolam (HM) group.  Subjects were evaluated by collecting data on incidence of  
PONV, post-operative pain, extra- pyramidal side effects, arrhythmias, and headache at  
0-2 hours and 2-24 hours post anesthesia (Honarmand et al., 2012).  The authors revealed  
the incidence of  PONV in the H group was 12 (60%), M group 13 (65%), HM group 5  
(25%) and C group 20 (100%) (Honarmand et al., 2012). The HM group also had the  
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highest incidence of complete response with 70% of the group denying PONV  
(Honarmand et al., 2012).  The study suggested that midazolam in combination  
with haloperidol decreases the incidence of PONV in the first 24 hours post anesthesia  
(Honarnamd et al., 2012).  
Propofol.   
Propofol, a lipophilic, sedative hypnotic medication, is commonly utilized for  
induction and maintenance of anesthesia.  Due to the quick onset and short duration of  
action,  propofol can be utilized for procedural sedation in the intensive care unit or the  
endoscopy department (Nagelhout & Elisha, 2018).  The anti-emetic mechanism of  
action for propofol still remains unclear however several mechanisms have been  
proposed. The proposals suggest that propofol directly depresses the vagal nuclei, the  
chemoreceptor trigger zone, and other areas contributing to nausea and vomiting  
(Miller & Gan, 2015).   
The study by Kim, Park, Kang, Choi, and Lee (2014), was a prospective, double- 
blind, randomized control trial of 107 women scheduled for a laparoscopy-assisted  
vaginal hysterectomy.  The authors evaluated the anti-emetic efficacy of propofol when  
administered at the conclusion of surgery (Kim et al., 2014).  The women were divided  
into three randomized groups: the control group, the 0.5 mg/kg propofol group, and the  
1mg/kg propofol group.  Data was collected on pain level, nausea, time spent in the post- 
operative unit, and use of rescue anti-emetics (Kim et al., 2014).  The authors revealed  
that the incidence of nausea was significantly lower in the two propofol groups compared  
to the control group (12.1%, 14.7%, and 40% respectively). The results showed that a  
low dose of  propofol can reduce the occurrence of PONV in the post anesthesia care unit   
(Kim et al., 2014). 
 Another study consisted of 120 subjects divided into three groups: propofol  
11 
 
group, dexamethasone group, and control group (Celik et al., 2015).  The data collected  
consisted of the incidence of nausea, vomiting, and rescue anti-emetic requirement.  Data  
was recorded at the following intervals: 0-6 hours, 6-12 hours, and 12-24 hours post  
anesthesia using a four-point post-operative nausea and vomiting scale (Celik et al.,  
2015).  The authors stated that the anti-emetic effects of propofol and dexamethasone  
were equivalent for the prevention of PONV in the first 24 hours post anesthesia. 
The study by Yimer, Ayalew, Abdisa & Aregawi (2017), was a prospective cohort study  
of 72 adults scheduled for open abdominal surgery.  The authors evaluated the efficacy of  
sub hypnotic dose of propofol on the incidence and severity of PONV.  The subjects were  
evenly allocated into two groups: the propofol and non-propofol group. Data collection  
included the incidence of PONV at intervals of 0-6h, 6-12h, 12-24h, hemodynamic  
parameters, respiratory depression,  severity of nausea and any side effects. (Yimer et al.,  
2017).   The severity of nausea was assessed utilizing a 11-point numerical scoring  
system and the Bellville scoring tool to assess nausea and vomiting.  The authors  
revealed that propofol at sub-hypnotic doses reduce the incidence of PONV in patients  
undergoing abdominal surgery electively and emergently.  According to Yimer et al.,  
(2017), the need for rescue anti-emetics was decreased in the propofol group compared to  
the non-propofol group.  
Midazolam.   
Midazolam, a benzodiazepine, is commonly used pre-operatively because of the  
anxiolytic and amnestic properties of the medication. The proposed anti-emetic  
mechanism of action of midazolam involves the reduction of dopamine input at the CTZ  
and potentially decreasing adenosine reuptake (Nagelhout & Elisha, 2018).  According to  
the meta-analysis by Grant et al. (2016) the use of midazolam significantly reduced  
rescue antiemetic requirement for the prevention of post-operative nausea and vomiting  
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in the adult population.  The authors further suggested that the use of midazolam alone or  
in combination with other antiemetics showed significant reduction in the incidence of  
PONV, nausea, and vomiting within the first 24 hours post anesthesia (Grant et al.,  
2016).  
 Another study consisting of 54 subjects scheduled for intragastric balloon  
insertion was divided into two groups: ondansetron and ondansetron/ midazolam group  
(Abdelhamid & Kamel, 2014).  Subjects were evaluated by collecting data on the  
incidence of nausea and vomiting, degree of sedation, nausea and vomiting score and  
incidence of adverse effects in the first 24 hours post anesthesia (Abdelhamid & Kamel,  
2014).  The authors revealed the incidence of nausea and vomiting was 17 (66% of  
subjects) in the ondansetron group and 9 (34.5% of subjects) in the ondansetron/  
midazolam group.  The authors further suggested the use of midazolam as an adjunct  
provides a significant reduction in PONV (Abdelhamid & Kamel, 2014). 





 In 2009, the Preferred Reporting Items of Systematic reviews and Meta-Analyses  
(PRISMA) statement or framework was developed to guide systematic review research.  
This framework was used to guide this major project.  The PRISMA framework consists  
of a four-phase flow diagram and a 27- item checklist (Liberati, Altman, Tetzlaff,  
Mulrow, Gøtzsche et al., 2009).  The flow diagram (See Appendix A) helps  
identify and organize research articles obtained for analysis based on inclusion and  
exclusion criteria (Liberati et al., 2009).  The four phases are identification, screening,  
eligibility, and included.  The checklist (See Appendix B) helps to analyze, organize, and  
develop a comprehensive selection of research articles for the systematic review (Liberati  
et al., 2009).  The checklist consists of six main sections: title, abstract, introduction,  
methods, results, discussion, and funding.  There are 27 subsections included in this  
organizational checklist.    
             Post-operative nausea and vomiting has been extensively researched by  
anesthesiologists, certified registered nurse anesthetists, and a combination of both  
over the past ten years (Gibbison & Spencer, 2009).  The pharmaceuticals used to  
manage PONV have changed over the years from individual medications to a multi- 
modal approach that is used currently.  Conducting a thorough and valid systematic  
review is the goal of this major project. PRISMA provides a framework to accomplish  
this goal.   







The purpose of this systematic review is to investigate the efficacy of propofol  
compared to midazolam on reducing the incidence of PONV in the adult population after  
general anesthesia. 
Inclusion/ Exclusion Criteria  
The inclusion criteria consisted of randomized control trials, meta-analyses, and  
cohort studies conducted within the last 10 years; adult subjects having elective surgery  
with general anesthesia; ASA I - II status; studies containing data for incidence of PONV,  
and articles in English. The PRISMA flowchart was utilized to identify and organize the  
articles based on this criterion. 
The exclusion criteria consisted of articles published over 10 years ago, subjects  
under the age of 18 years old, subjects with history of drug or alcohol abuse, history of  
renal, kidney or liver disease and studies without data on the incidence of PONV after  
general anesthesia. The PRISMA flowchart was utilized to identify and organize the  
articles based on this criterion.  
Search Strategy 
Research articles were obtained by conducting a through database search on  
CINAHL, Medline, PubMed, and Google Scholar.  The search terms included post- 
operative nausea and vomiting, general anesthesia side effects, propofol, midazolam,  
PONV prevention, prophylaxis treatment of PONV, and anti-emetics.  
Data Collection 
After article selection, two data collection tables were created for each article  
included in the systematic review. Table 1 includes the demographics of each study  





Demographics of Study 
Citation 
 Aim        Design        Sample        Method        Procedures      Medication Used/ Results 
________________________________________________________________________ 
Table 2 contains the results of each study including the citation, incidence of nausea  
and vomiting, use of other anti-emetics, opioid use, induction/ maintenance medications, 
and limitations (See Appendix D). 
Table 2  
Study Results 
Citation 




The Critical Appraisal Skills Programme (CASP) was utilized to evaluate the  
validity of the research articles selected for this systematic review (Critical Appraisal  
Skills Programme, 2018). The CASP checklist (See Appendix E) consists of 10-questions  
to confirm that the selected studies correlate to the purpose of the systematic review. The  
checklist includes the following three sections: validity, results, and applicability to  
practice (Critical Appraisal Skills Programme, 2018).  Once data collection and the  
CASP checklist was completed (See Appendix F), a cross-study analysis tables was 
created to analyze incidence of nausea and vomiting, use of other rescue anti-emetics,  
adverse effects, and opioid use (Table 3, See Appendix G). 
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Table 3   
Cross-Study Analysis 
Study #          N/ V       Rescue Anti-Emetics         Adverse Effects         Opioid Use           
________________________________________________________________________ 





After a comprehensive database search 72 articles were retrieved for screening.  The  
PRISMA flowchart (Appendix A) was used to guide, organize, eliminate duplicates, and  
further screen the appropriate articles based on inclusion and exclusion criteria.  After  
duplicates were removed, 31 articles remained, 15 full text articles were then screened,  
and 7 more were then excluded based on lack of appropriate data.  The eight remaining  
articles were included in the systematic review consisting of seven randomized control  
trials and one prospective cohort study.  The results presented here were extracted from  
the data collection tables (Appendix D 1-8), and cross-study analysis table (Appendix G)  
created by the author. 
 The study by Abdelhamid et al. (2014) was a prospective randomized control trial  
consisting of 54 subjects aged 18-40 with an ASA physical status of I or II presenting for  
intragastric balloon insertion surgery.  The incidence of PONV, nausea/ vomiting score,  
and degree of sedation were collected immediately in PACU, then at intervals of 30- and  
60-minutes post-anesthesia.  Incidence of adverse effects were collected during the first  
24 hours post-anesthesia.  The subjects were randomly allocated into two groups:  
ondansetron group (8mg) and the ondansetron / midazolam group (8mg/ 0.075mcg/kg).   
Anesthesia induction was universal in all cases using fentanyl, propofol, cisatracurium  
and maintenance consisted of propofol infusion.  The data was analyzed using SPSS 18  
software, Kolmogorov-Smirnov test, t-test, Chi-square test, Monte Carlo test, Fisher’s  
exact test and p value of < 0.05 was considered significant.  The authors revealed the  
incidence of PONV in first 24 hours in ondansetron only group was 14 (56%) compared 
to 10 (34.5%) in the ondansetron/ midazolam group (P=0.113).  According to  
Abdelhamid et al. (2014) there was not significant reduction in incidence of PONV  
(P=0.113), however there was a significant difference in nausea/ vomiting scores  
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(P=0.015) in the first 24-hour period. The study revealed in the ondansetron group (G1)   
11 (44%) without nausea or vomiting, 0 with nausea only, 4 (16%) with vomiting only,  
and 10 (40%) with both nausea and vomiting.  They further revealed in the ondansetron/  
midazolam group (G2) 19 (65.5%) without nausea or vomiting, 3 (10.3%) with nausea  
only, 0 with vomiting only, and 7 (24.1%) with both nausea and vomiting.  Regarding  
sedation, 20 (80%) of ondansetron group were mildly sedated immediately post  
compared to 17 (58.6%) in group 2 (P=0.018). Then 30 minutes after surgery zero were  
mildly sedated in ondansetron group compared to 7 (24.1%) in group 2 (P=0.012).  The  
limitations of this study included lack of control group, no other side effect data was  
collected other than sedation, uneven subjects per group, and no mention of rescue anti- 
emetic requirement.  The authors suggested that midazolam/ ondansetron significantly  
reduced the severity of PONV according to nausea/ vomiting scores but not the overall  
incidence of PONV.   
 The randomized, double blind, placebo-controlled study by Celik et al. (2014)  
consisted of 120 adult subjects, both male and female with ASA status I or II presenting  
for laparoscopic cholecystectomy.  The purpose of the study was to evaluate the efficacy  
of sub-hypnotic dose propofol with dexamethasone on the incidence of PONV.   The  
subjects were randomly assigned to one of three groups: propofol, dexamethasone, or the  
control group (n=40).  The data collected included incidence of PONV, rescue anti- 
emetic requirement, and rescue analgesic needed in the first 24 hours post-surgery.   
Nausea, vomiting and anti-emetic usage was recorded at intervals of 0-6h, 6-12h, and 12- 
24h.  The visual analog scale and PONV four-point scale were used to quantify nausea  
and severity of vomiting.  Induction of anesthesia was universal for all cases using  
thiopental sodium 5mg/kg, fentanyl 1mcg/kg,  and rocuronium for paralytic.  Anesthesia  
was maintained with 1-2.5% sevoflurane,  50% oxygen and fentanyl 1mcg/kg/h in the  
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dexamethasone group(Group D) and propofol infusion 1mg/kg/h in propofol group  
(Group P).  The data was analyzed using the program of SPSS 20, ANOVA, Chi-test and  
a p value of < 0.05 was considered significant. The study revealed significant reduction in  
PONV between the control group and the group P and group D at all three-time intervals  
(P< 0.05).  At the 0-6h interval 65% of the control group experienced PONV compared to  
30% in the other two groups (P< 0.05). At the 6-12h interval there was a significant  
reduction among the groups, 52.5% of control group, 25 % of propofol group, 20% of  
dexamethasone group experienced PONV (P < 0.05 when compared to control group).  
The study also showed significant difference in number of subjects requiring rescue anti- 
emetics in the control group 13 (32.5%) compared to the propofol group 4 (10%) and the  
dexamethasone group 4 (10%) (P=0.01 for both).  There was no significant difference in  
analgesic requirements between the propofol and dexamethasone groups, however there  
was a significant difference between the control and dexamethasone groups (P=0.04).  
 The next randomized control study by Heidari et al. (2012) consisted of 66  
subjects aged 18-65 with an ASA status of I or II presenting for elective middle ear  
surgery.  The subjects weighed less than 100 kg without history of motion sickness or  
PONV and denied hypersensitivity to midazolam or dexamethasone.  The aim of this  
study was to compare the efficacy of midazolam and midazolam plus dexamethasone on  
the incidence of PONV.  The subjects were randomly divided into two groups: the  
midazolam group (0.075 mg/kg) and the midazolam (0.075 mg/kg) plus dexamethasone  
(0.05 mg/kg) group. Induction and maintenance of anesthesia were standardized for all  
subjects.   Data collection consisted of the incidence of PONV, severity of nausea/  
vomiting measured via VAS (0-10) in PACU, 0-6h, 6-12h, and 12-24h intervals and  
rescue anti-emetic requirements. The data was analyzed with a Chi-square, t-test, and p  
value < 0.05 was considered significant.  The authors revealed a mean nausea score of  
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1.39 ±3.19 in the midazolam group (P=0.049) and 0.42 ± 1.71 in the midazolam/  
dexamethasone group (P=0.049) and rescue anti-emetic requirements were higher in the  
midazolam group (12.9 ± 23.44 mg) compared to the combination group (6.48 ±9.54mg)  
(P <0.05 for both).  The mean vomiting frequency in the PACU (P=0.039), at intervals of  
6-12h (P=0.04) and 12-24h (P=0.047) were significantly different between the groups.   
The authors revealed that midazolam does have some anti-emetic properties however in  
combination with dexamethasone the effects were superior to single medication therapy.    
The limitations of this study included lack of control group and small sample size  
therefore, further studies would be needed to better compare these medications on  
preventing and / or reducing the incidence of PONV.  
 The randomized, double-blind, placebo-controlled study by Honarmand et al.  
(2012) consisted of 80 subjects aged 18-60 with an ASA status of I or II presenting for  
middle ear surgery under general anesthesia.   The subjects were randomly and evenly  
allocated into one of four groups (n=20).  The haloperidol group (2mg), midazolam group  
(2mg), haloperidol/ midazolam group (2mg of each), or the control group (saline).  Both  
induction and maintenance of anesthesia were standardized in all cases.  The data  
collection consisted of incidence of PONV, complete response to treatment, pain,  
occurrence of side effects (arrhythmias, headache), and rescue anti-emetic requirement 
at three intervals: 0-2h, 2-24h, 0-24h.  Tests used to analyze data were ANOVA, Pearson  
Chi-square test, Fisher’s exact test, Mann-Whitney U-test, SPSS 16.0 software and p  
value of <0.05 was considered significant.   The authors revealed comparable  
complete response between the haloperidol and control group with 20% of the group  
without PONV.  The midazolam group had a 45% complete response (P< 0.05) and the  
haloperidol/ midazolam had a 70% complete response (P<0.05).  Further comparison  
revealed that haloperidol/midazolam was more effective than midazolam only at the 2- 
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24h and 0-24h intervals (P< 0.05 for both).  According to Honarmand et al. (2012),  the  
midazolam and haloperidol group rescue anti-emetic requirements were comparable  
however the haloperidol/midazolam group requirement (0.5± 1.5mg) was significantly  
less than the other three groups [2.0- 6.5±4.1- 4.6mg (p< 0.05)].  The study further  
revealed no significant differences in side effects, sedation, VAS score, or post-operative  
analgesic requirement.  The limitations of the study included small sample size and  
severity of nausea was not evaluated.   
 Next, the prospective randomized study by Joe et al. (2016) consisted of 72  
females aged 20-60 with an ASA status of I or II presenting for thyroidectomy under  
general anesthesia.  The purpose of study was to evaluate the efficacy of combined  
ramosetron and total intravenous anesthesia (TIVA) on the incidence of PONV.  The  
subjects were allocated into either the sevoflurane group or the TIVA with ramosetron  
group (n=36).  Data collection included incidence and severity of PONV and rescue anti- 
emetic requirements for each group at intervals of 0-6h, 6-24h, and 0-24h post-surgery.   
The data was analyzed using SPSS 17.0 program, Student’s t-test, x²-test, and p values of  
< 0.05 were considered significant. The study revealed a significant reduction of PONV  
and reduced rescue anti-emetic requirements in the TIVA group at all intervals compared  
to the other group. In the first 24h, 7 (19.4%) in TIVA group and 22 (61.1%) in  
sevoflurane group experienced PONV (P=0.001), and 4 (11.1%) and 15 (41.7%) needed  
rescue anti-emetic respectively (P=0.007).  Therefore, the authors suggest the use of  
TIVA over the use of volatile anesthetics at reducing the incidence of PONV. The  
limitations of this study include lack of TIVA control group and small sample size.   
 The prospective, double-blind randomized control study by Kim et al. (2014)  
consisted of 107 females with ASA status of I or II presenting for laparoscopy assisted  
vaginal hysterectomy under general anesthesia.  The aim of this study was to evaluate the  
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antiemetic effect of varying doses of propofol given prior to end of surgery. The subjects  
were allocated into 1 of 3 groups: the propofol 0.5 mg/kg group, propofol 1 mg/kg group  
or the control saline group.  Induction and maintenance of anesthesia were universal for  
all cases and propofol or saline were given 15 minutes prior to end of case.   Data  
collection included incidence of PONV and nausea/vomiting severity at 0-2h, 2-24h, and  
24-48h post-surgery.   The data was analyzed using SPSS 18.0, Sigma Stat 12.0, Chi- 
square test, Fisher’s exact test, ANOVA, and a p value of <0.05 was considered  
significant.  The authors used the visual analog scale (0-10) to quantify nausea/ 
vomiting severity.  The study revealed a significant reduction of PONV (P=0.007) and  
less need for rescue anti-emetics (P=0.026) in both the propofol groups compared to the  
control group.  At the 0-2h interval, the incidence of PONV for the control group was 16  
(P=0.007),  propofol (0.5mg/kg) 4 (P=00.07), and propofol (1mg/kg) 5 (P=0.007).  The  
authors showed no significant difference between the propofol doses on the incidence of  
PONV (4 and 5 respectively) and rescue anti-emetic requirement (1 and 2 respectively).   
The authors further revealed prolonged emergence period in the propofol groups  
compared to the control group (P=0.038 and P=0.006 respectively). The limitations of  
this study includes relatively small sample size and no comparison between propofol and   
other anti-emetics.  According to Kim et al. (2014) even though propofol prolonged  
emergence, it effectively reduced the incidence of PONV and rescue anti-emetic  
requirements, therefore proving to be a positive adjunct to the anesthetic plan.   
 Another prospective, randomized, double-blind, placebo-controlled study by  
Naghibi et al. (2015) consisted of 104 subjects aged 18-65 years with ASA status I or II  
and BMI < 30 kg/m² presenting for elective lower abdominal surgery under general  
anesthesia.  The purpose of this study was to compare the effects of sub-hypnotic dose of  
propofol with metoclopramide.  The subjects were randomly assigned into 1 of 4 groups:  
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propofol 20mg (G1), propofol 30mg (G2), metoclopramide 10mg (G3), or placebo saline  
group (G4).  Data collection consisted of incidence and severity of PONV, side effects of  
anti-emetics, duration of surgery and recovery period recorded at 0-6h, 6-12h, and 12-24h  
intervals.  Induction and maintenance of anesthesia was universal in all cases and  
baseline hemodynamic were also collected.  The data was analyzed using SPSS 20  
software, Student’s t-test, x²- test, ANOVA, and p value of <0.05 was considered  
significant.   The study revealed significant reduction in PONV in the propofol groups  
compared to the control. The incidence of PONV 0-6h post-anesthesia was 6 (23.08%) in  
G1 (P=0.005), 4 (15.38%) in G2 (P=0.016), 4 (15.38%) in G3 (P=0.016), and 8 (30.77%)  
in G4 (P=0.005) (Kim et al., 2014).  However, the propofol groups were comparable at  
reducing PONV and the propofol 30 mg group was also comparable to the  
metoclopramide group (P=0.016).  There was less rescue anti-emetic requirement in both  
propofol groups and metoclopramide group compared to the control group (P=0.042).   
The authors revealed the mean dose of anti-emetic was comparable in both propofol  
group (5.2±2.1 mg vs 5±0.9 mg) and metoclopramide group (6±1.8 mg).  No side effects  
were noted in the  study and limitations of this study included small sample size and  
subjects were followed for first 24 hours post-surgery.   
 Lastly a prospective cohort study by Yimer et al. (2017) consisted of 72 subjects  
aged 18 or older with ASA status of I or II presenting for open abdominal surgery under  
general anesthesia.  The aim of this study was to assess the efficacy of sub-hypnotic dose  
of propofol on the incidence of PONV.  Data collection included the incidence of PONV  
at intervals of 0-6h, 6-12h, 12-24h, hemodynamic parameters, respiratory depression,   
severity of nausea and any side effects.  Induction and maintenance of anesthesia were  
universal for all cases.  The data was analyzed using SPSS 20 software, Student’s t-test,  
Fisher’s exact test, Shapiro-Wilk normality test, Mann-Whitney U test, Chi-square test,  
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and p value <0.05 was considered significant. The authors revealed significant reduction  
in PONV in the propofol group 11 (30.6%) in the first 6 hours compared to the control  
group  24 (66.7%) (P=0.002), no significant differences in hemodynamic stability and  
respiratory depression and noted more severe nausea in the control group.  The study also  
showed a significant reduction in rescue anti-emetic needed in the propofol group  
compared to the control group [5 (13.9%) and 15 (41.7%) respectively, (P=0.009)].  The  
limitations of this study included lack of group randomization; lack of anti-emetic used  
after 6 hours post-surgery, and the subjects were followed for the first 24 hours post- 
operatively.   
 All eight research articles were analyzed using the CASP appraisal tool to  
evaluate the validity of the research article and applicability to practice (Appendix F 1-8).   
Seven of the eight articles had 9 out of  9  “yes” to the appraisal questions (Abdelhamid  
et al. F-1,Celik et al., F-2, Heidari et al. F-3, Honarmand et al. F-4, Joe et al. F-5,Kim et  
al. F-6, Naghibi et al. F-7). All seven articles were deemed valid for this systematic  
review and the results were applicable to advanced nursing practice.  The article by  
Yimer et al. was a prospective cohort study and the subjects were not randomized but  
were evenly allocated to either the propofol group or non-propofol group.  Even though  
the subjects were not randomized due to university rules, the nature and results of the  
study showed enough validity to be included in this systematic review.  Furthermore, the  
results of this study were considered applicable to advanced nursing practice. 






Summary and Conclusions 
Post-operative nausea and vomiting (PONV) is defined as the occurrence of  
nausea, vomiting or retching after a surgical procedure either in PACU or within 24 hours  
after surgery (Horn, Wallisch, Homantics & Williams, 2014).  PONV, the second leading  
problem faced in the post-anesthesia care unit, can affect 30 -80% of surgical patients  
based on patient-specific and anesthetic specific risk factors (Abdelhamid & Kamel,  
2014).  The patient-related risk factors of PONV  include female gender, non-smoker,  
history of PONV, history of motion sickness, and age less than 50 years old.  Anesthetic  
related factors include use of volatile gases, use of nitrous oxide, duration, and type of the  
surgery, and post-operative opioid use (Moon,2014). PONV contributes to unfavorable  
consequences like delayed recovery, pulmonary aspiration, unexpected hospital  
admission or increased length of stay, delayed return to work, wound dehiscence and  
dehydration.  Furthermore, risk of PONV may be quantified by using scoring systems  
such as the Apfel or the Visual Analog System (VAS).  The Apfel scoring system  
consists of four factors: gender, smoking status, history of motion sickness or PONV, and  
use of post-operative opioids (Apfel et al. (2012).  The Apfel score ranges from 0-4,  
predicting the percentage of PONV risk in the first 24 hours post-operatively.   The VAS  
quantifies the severity of nausea / vomiting using a 0-10 scale. 
 A systematic review was conducted to investigate the efficacy of propofol  
compared to midazolam on reducing the incidence of post-operative nausea and vomiting  
in the adult population after general anesthesia.  A review of literature was conducted  
using the PRISMA flow chart (Appendix A) along with inclusion and exclusion criteria  
set forth by the author.  The data collected consisted of incidence of PONV, rescue anti- 
emetic requirement, induction/ maintenance medication used, side effects, and  
limitations (Appendix D 1-8).   Eight articles were included in the systematic review ,  
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seven random control trials and one prospective cohort study.  Data collection tables were  
created, CASP checklist (See Appendix E & F) was utilized to appraise each article  
included in the review and a cross-study analysis table (See Appendix G) was created and  
used to validate and compare the results of each article.    
 All the studies in this systematic review revealed that both propofol and  
midazolam possesses anti-emetic properties.  The review further suggests that both  
medications significantly reduced the incidence of PONV (See Appendix D 1-8,  
Appendix G) and seven studies revealed reduction in rescue anti-emetic requirements  
with the use of either propofol or midazolam.   However, four out of eight studies  
revealed a multimodal approach was far superior at reducing the incidence of PONV  
compared to single agent approach.   The study by Heidari et al. (2012) showed  
midazolam alone was effective at  reducing the incidence of PONV however adding  
dexamethasone had significant impact on reducing the incidence and reduced the anti- 
emetic requirement by half.  This systematic review supports the usage of these  
medications in a multimodal approach and proven effective at reducing and preventing  
PONV in the adult population after general anesthesia.  Limitations to this study include  
limited number of studies analyzed for the review; type of surgeries involved in the  
studies because specific surgeries increase risk of PONV, one of the eight studies made  
no mention of rescue anti-emetics, and small sample sizes of some studies included in the  
systematic review.   
 In conclusion, both propofol and midazolam were shown to reduce the incidence  
and severity of PONV in the adult population following general anesthesia.  The  
results of this systematic review can give certified registered nurse anesthetists (CRNA)  
more options in the multimodal approach in the preventing and reducing the incidence of  
PONV.  Next, recommendations and implications for advanced nursing practice. 
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Recommendations and Implications for Advanced Nursing Practice 
The systematic review revealed information that can be valuable to the advanced  
practice provider to incorporate into practice in order to reduce and/ or prevent the  
incidence  and/or severity of PONV in the adult population.  PONV can affect 30-80% of  
the surgical population, therefore, CRNA’s play a crucial role in planning and  
implementing treatment to reduce and/ or prevent incidence of PONV.  Advanced  
practice providers incorporate evidence-based research, guidelines, and algorithms into  
daily practice, therefore, information obtained from this systematic review would be  
beneficial.  Analyzing the risk factors can assist the CRNA at creating a more appropriate  
plan of care to decrease the incidence of PONV.  Implementing protocols to prophy-  
lactically treat PONV would reduce the adverse outcomes of anesthesia.   
 As CRNAs, a through preoperative assessment is key to determining which  
patients are at increased risk of PONV by utilizing the assessment tools available (i.e., 
Apfel, Bellville).  Discussing the potential risk with the patient can help to lessen anxiety  
and potentially reduce the risk of PONV.  After determining the patient’s risk of PONV,  
the anesthesia provider can utilize the SAMBA algorithm (see Figure 1) to create an  
appropriate plan of care (Hooper, 2015).  As stated earlier, specific surgeries  
pose an increased risk for PONV and those patients would benefit from a multimodal  
approach for preventing and reducing PONV.  CRNAs understand PONV is  
multifactorial and most patients require a minimum of two anti-emetics, therefore, adding  
a sub-hypnotic dose of propofol or pre-operative dose of midazolam proves safe and  
effective in prophylactically treating PONV.  With guidelines or protocols in place and  
continuing education for anesthesia providers, prophylactically treating PONV shall  
become an easier task.  Increased awareness of the multiple drug options for management  
shall help minimize the incidence of PONV, such as utilizing a preoperative sub-hypnotic  
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midazolam dose not only for anxiolysis but also for the prevention of PONV.  Even  
though this review suggests effective reduction of PONV with the use of propofol or 
midazolam alone or in combination with other anti-emetics, further research on this  
topic is needed due to rapid pharmaceutical advancements.    
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 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
Records identified through 
PubMed database searching 
(n = 40) 























n Additional records identified 
through other sources 
(n =32) 
Records after duplicates removed 
(n = 31) 
Records screened 
(n = 31) 
Records excluded 
(n = 16) 
Full-text articles assessed 
for eligibility 
(n = 15) 
Full-text articles 
excluded, with reasons 
(n = 7) 
Studies included in 
qualitative synthesis 
(n =   8) 
35 
 
 Appendix B  
PRISMA Checklist 
 
Page  1 of 2 
 
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed100009 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 








                                                                              Page 2 of 2 
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  




Demographics of Study 
C-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the antiemetic effect of midazolam following 
intragastric balloon insertion. Journal of Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/0970-
9185.137272     
Aim/ Purpose      Design                 Sample                Methods                    Procedure               Medication Used/ Results 
To investigate 
















8 mg and 
ondansetron/ 
midazolam group  
8mg/ 0.075mcg/kg 
(based on total 
body weight) 
54 subjects, aged 
18-40, ASA 
physical status I -





The incidence of 
nausea and vomiting, 
nausea/ vomiting 
score, the degree of 
sedation 
(immediately, 30 
minutes, and 60 
minutes post-
anesthesia) incidence 
of adverse effects 





and maintenance was 












Significant reduction in the 
severity of PONV in the 
combination group compared 
to ondansetron group.  
 
Mild sedation occurred in early 
post-operative period.  
 
Nausea/ vomiting during 24h 
post-operatively in group 1 
was 56%  (14 subjects) and 




C-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat Erdem, A. (2014). Is infusion of sub hypnotic 
propofol as effective as dexamethasone in prevention of post-operative nausea and vomiting related to laparoscopic cholecystectomy? 
A randomized controlled trial. BioMed Research International, 2015, 1-5. https://dx.doi.org/10.1155/2015/349806 
Aim/ Purpose     Design                 Sample           Methods                        Procedure               Medication Used/ Results 
Evaluate the 

















(8mg), or control 








physical status I 
or II presenting 
for laparoscopic 
cholecystectomy  
Incidence of PONV, need 
for rescue anti-emetic or 
rescue analgesic recorded 
in the first 24 hours post 
anesthesia 
Nausea, vomiting, anti-
emetic use was recorded at 
3 periods: 0-6hours, 6-
12hours, and 12-24 hours 
Visual Analog Scale and 
PONV four-point scale 
Anesthesia induction and 
maintenance was universal 
in all cases 
Laparoscopic 
cholecystectomy 
Dexamethasone 8 mg 
Propofol 1mg/kg/hour 
Control 10% intralipids 




comparable in 0-24-hour 
post anesthesia period 
Dexamethasone group 
required less rescue anti-
emetic in 6-12 hours and 







C-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect of midazolam and midazolam-




To evaluate the 
efficacy of  
midazolam and  
midazolam plus 
dexamethasone 











66 ASA I or II, aged 
18-65, weight < 
100kg without 
history of motion 
sickness, pregnancy, 
hypersensitivity to 





Subjects randomly divided into 2 
groups: midazolam (M) 
(0.075mg/kg) and midazolam 
(0.075 mg/kg) plus 




standardized for all subjects, 
universal monitoring for all 
subjects 
 
Severity of nausea /vomiting 
measured by visual analog scale 
in PACU, at 6,12, and 24h after 
surgery, rescue anti-emetics and 
PACU length of stay was also 
recorded 
 
Rescue anti-emetic was 








Medication Used/ Results 
 
No significant 
differences in age, 
weight, and gender 
between the groups 
 
Mean nausea score 
M group: 1.39 ±3.19 




PACU: 0.9 ± 0.29 (M),  
0 ±0 (M+D) 
6-12h: 1.09 ±2.41 (M) 
0.3 ± 0.8 (M+D) 
12-24h: 0.42± 1.32 (M), 
0.03 ± 0.17 
 
Rescue Antiemetic 
M: 12.9 ± 23.44 





C-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic administration of haloperidol plus 
midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear 
surgery. Saudi Journal of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028 
Aim/Purpose 
 
To evaluate the 
anti-emetic 



















Group H: (n=20) 
Haloperidol 2 mg IV 
 
Group M: (n=20) 
Midazolam 2 mg IV 
 
Group HM: (n=20) 
Haloperidol 2 mg IV 
Midazolam 2 mg IV 
 








80 ASA status 












haloperidol or both 
were given 30 min 
before conclusion of 
surgery 
 
Data on incidence of 
PONV, complete 
response, pain, 
occurrence of side 
effects, arrhythmias, 
rescue anti-emetics 
and headache was 
collected for 0-2h, 2-
24h, & 0-24h, VAS 











Medication used/ Results 
 
Group H:  
Complete Response 4 (20%) 
0-2h: 6 (30%) 
2-24h: 6 (30%) 
0-24h: 12 (60%) 
 
Group M:  
Complete Response 9 (45%) 
0-2h: 9 (45%) 
2-24h: 4 (20%) 
0-24h: 13 (65%) 
 
Group HM:  
Complete Response 14 
(70%) 
0-2h: 3 (15%) 
2-24h: 2 (10%) 
0-24h: 5 (25%) 
 
Group C:  
Complete Response 4 (20%) 
0-2h: 10 (50%) 
2-24h: 10 (50%) 




C-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S. Y. (2016). Effect of total intravenous anesthesia 
and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized controlled study. 
Journal of International Medical Research, 44(1), 81–88. https://doi.org/10.1177/0300060515607384 
Aim/ Purpose 
 





































Incidence and severity of 
PONV, use of rescue anti-
emetics were recorded 




induced with 4-5mg/kg 
thiopental sodium, 
maintained with 
sevoflurane in 50% 
oxygen 
 
TIVAR group 0.3 mg 
ramsetron IV given prior 
to induction with 
remifentanil, propofol 
All other medication was 
universal in both groups 
 
Post-operative 
assessments made at 1h, 
6h, 24h, incidence of 

















Medication Used/ Results 
 
TIVAR Group  
0-6h:  
PONV: 4 (11.1%) 
Rescue Antiemetic: 2 (5.6%) 
6-24h: 
PONV: 6 (16.7%) 
Rescue Antiemetic: 3 (8.3%) 
0-24h: 
PONV: 7 (19.4%) 




PONV: 20 (55.6%) 




Rescue Antiemetic: 6 (16.7%) 
0-24h: 
PONV: 22 (61.1%) 









C-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol administered at the end of surgery in 




To evaluate the 
efficacy of 
varying doses of 
propofol given 
15 minutes prior 

























placed into 3 
groups (0.5 mg/kg 

















Visual Analog Scale (VAS)  
 
Incidence of PONV post-
operative in time intervals 
(0-2 hours, 2-24 hours, 24-48 
hours) 
 
Anesthesia induction and 






























0.5 mg/kg propofol, 
1mg/kg propofol, 
normal saline (control) 
 
Incidence of nausea:  
0-2 hours 
Group 1: 4 (12%) 
Group 2: 5  (15%) 
Control: 16  (40%) 
  
Incidence of vomiting: 
0-2 hours 
Group 1: 0 
Group 2: 2 (6%) 
Control: 3 (8%) 
 
No significant effect in 
2-24-hour, 24-48-hour 




C-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015).  Prevention of postoperative nausea and vomiting with sub 
hypnotic dose of propofol in patients undergoing lower abdominal surgery: A prospective, randomized, double-blind study. 
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239 
Aim/ Purpose 

















into 1 of 4 groups: 
propofol 20 mg, 
propofol 30 mg,  
metoclopramide 10 






status I or II, aged 









Incidence and severity 
of PONV, Side effects 
of anti-emetics were 
recorded during the 
first 24 hours post 
anesthesia (0-6h,6-
12h, 12-24h), 
duration of surgery 
and recovery period 
was collected 
 
Baseline HR, SBP, 




and maintenance was 












Medication Used/ Results 
 
Propofol 20 mg, 
Propofol 30 mg, 
Metoclopramide 10mg, or 
Saline given 15 minutes 
prior to skin closure 
 
Propofol 30 mg was 
slightly more effective 
than Metoclopramide 10 
mg in the first 6 hours 
post anesthesia  
 
Both groups had 15.39% 
N/V but propofol group 






C-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic dose of propofol on prevention of postoperative 
nausea and vomiting as part of multimodal antiemetic in patients undergoing open abdominal surgery: A prospective cohort study. 
International Journal of Surgery Open, 10(2018), 15-20. https://doi.org/10.1016/j.ijso.2017.11.008 
Aim/Purpose 
 





































72 subjects, >18 
years old, ASA I 







Incidence of PONV at 
intervals of 0-6h, 6-12h, 
12-24h, hemodynamic 
parameters, respiratory 












vecuronium halothane  
with or without morphine  
 
Reversal:  
neostigmine 0.05mg/kg  

























0-6h: 11 (30.6%) 
6-12h: 8 (22.2%) 
12-24h: 7 (19.4%) 
 
Control group: 
0-6h: 24 (66.7%) 
6-12h: 14 (38.9%) 
12-24h: 9 (25%) 
 
No significant differences 
in hemodynamic stability, 
respiratory depression 
 
Severity of nausea greater 









Results of Study 
D-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the antiemetic effect of midazolam following 
intragastric balloon insertion. Journal of Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/0970-
9185.137272 
Nausea & Vomiting 
 
Incidence of N/V: 
Group 1: Ondansetron  
only14 (56%) 
 
Group 2: Ondansetron  
& midazolam group:  
10 (34.5%) 
 
Vomiting only:  
Group 1: 4 (16%) 
Group 2: none 
N/V score: 
Group 1:11 (44%): no nausea, 
no vomiting, 0 (0%): nausea 
only, 4 (16%): vomiting only, 10 
(40%): nausea and vomiting 
 
Group 2: 19 (65.6%): no nausea, 
no vomiting, 3 (10.3%): nausea 
only0 (0%): vomiting only, 7 




No mention of 
rescue anti-






fentanyl  1mcg/kg  
propofol 2-2.5 mg/kg 








Level of sedation was measured 
immediately post-operatively, 30-
minutes post, and 60 minutes post 
 
Group 1:Immediately Post: 
4 (16%) awake, 20 (80%) mildly 
sedated, 1 (4%) moderately 
sedated 
30 minutes post: 25 (100%) 
awake,0 mildly sedated 
60 minutes post: 25 (100%) awake 
 
Group2: Immediately Post: 
2 (6.9%) awake, 17 (58.6%) 
mildly sedated 
10 (34.5%) moderately sedated 
30 minutes post: 22 (75.9%) 
awake, 
7 (24.1%) mildly sedated 
60 minutes post: All subjects were 
















D-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat Erdem, A. (2014). Is infusion of sub 
hypnotic propofol as effective as dexamethasone in prevention of post-operative nausea and vomiting related to laparoscopic 
cholecystectomy? A randomized controlled trial. BioMed Research International, 2015, 1-
5.https://dx.doi.org/10.1155/2015/349806 
Nausea & Vomiting 
 
0-6 hours post: 
Group C: 65% 
Group P: 30% 
Group D: 30% 
 
6-12 hours post: 
Group C: 52.5% 
Group P: 25% 
Group D: 20% 
 
12-24 hours post: 
Group C: 45% 
Group P: 20% 





0-6 hours post: 
Group C: 13 (32.5%) 
Group P: 4 (10%) 
Group D: 4 (10%) 
 
6-12 hours post: 
Group C: (20%) 
Group P: (7.5%) 
Group D: (2.5%) 
 
12-24 hours post: 
No significant 
differences among 














Induction: both groups 
Thiopental sodium 5 mg/kg 




Group D:  
1.0-2.5 % Sevoflurane with 50% 
oxygen 
Fentanyl 1 mcg/kg/h 
 
Group P: propofol 1mg/kg/h 
Side Effects 
 
There was no significant 




Group C: 6.1 ± 1.2 min 
Group P: 6.2 ± 1.21 min 
Group D: 5.9 ± 1.24 min 
Limitations 
 
Type of surgery 








D-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect of midazolam and midazolam-
dexamethasone on postoperative nausea and vomiting in elective middle ear surgery. Advanced Biomedical Research, 1(9), 1-9. 
http://doi:10.4103/2277-9175.96052 
Nausea & Vomiting 
 
Mean nausea score 
Midazolam group (M):  
1.39 ±3.19 
Midazolam/ Dexamethasone 
group (M+D): 0.42 ±1.71 
 
Mean Vomiting frequency: 
PACU: 0.9 ± 0.29 (M), 0 ±0 
(M+D) 
6-12h: 1.09 ±2.41 (M) 
0.3± 0.8 (M+D) 
12-24h: 0.42± 1.32 (M), 















M group:  
12.9 ± 23.44 
M+D group:  





Thiopental sodium 5 mg/kg 




Nitrous oxide 50% in Oxygen 50% 
Morphine 0.1 mg/kg 
 
Neuromuscular blocker reversal 
Neostigmine 0.4 mg/kg 




time in PACU in 
midazolam group 










D-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic administration of haloperidol plus 
midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear 
surgery. Saudi Journal of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028 
Nausea & Vomiting 
 
Haloperidol Group:  
Complete Response 4 (20%) 
0-2h: 6 (30%) 
2-24h: 6 (30%) 
0-24h: 12 (60%) 
 
Midazolam Group:  
Complete Response 9 (45%) 
0-2h: 9 (45%) 
2-24h: 4 (20%) 




Complete Response 14 
(70%) 
0-2h: 3 (15%) 
2-24h: 2 (10%) 
0-24h: 5 (25%) 
 
Control Group:  
Complete Response 4 (20%) 
0-2h: 10 (50%) 
2-24h: 10 (50%) 




ondansetron 4 mg IV 
 
M Group: 2.0 ± 4.1 
H Group: 2.5 ± 4.4 
HM Group: 0.5 ± 1.5 
C Group: 6.5 ±4.6 
 
Time to first demand: 
Group M: 3.4 ± 1.6 h 
Group H: 2.3 ±2.2 h 
Group HM: 12.1 ± 
3.4 h 
Group C: 0.4 ± 0.5 h 
Induction/ Maintenance Meds 
 
Induction: 
Thiopental sodium 5 mg/kg 
Fentanyl 3 mcg/kg 
Atracurium 0.6 mg/kg 
 
Maintenance: 
Morphine 1 mg/kg PRN 
Isoflurane 1.2% 




Neostigmine 0.04 mg/kg 






Group M: Headache: 2 
Group HM: Headache: 2 
Group C: Headache: 2 
 
Sedation: minutes after 
arrival to PACU 
5 min: 3 in each group 
15 min: 2.5 in H group, 2 
in Group M, HM, C 
30 min: 1 in Group H, 
HM, C, 1.5 in Group M 
60 min: 1 in Group H, 2 
in Group M, HM, C 
120 min: 1 in each group 
 
No significant difference 




















D-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S. Y. (2016). Effect of total intravenous 
anesthesia and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized 
controlled study. Journal of International Medical Research, 44(1), 81–88. https://doi.org/10.1177/0300060515607384 
Nausea & Vomiting 
 


























0-6h: 2 (5.6%) 
6-24h: 3 (8.3%) 
0-24h: 4 ( 11.1%) 
 
Sevoflurane Group: 
0-6h: 11 (32.4%) 
6-24h: 6 (16.7%) 




Thiopental sodium 4-5 mg/kg 
Sevoflurane in 50% oxygen 
 
TIVAR Group: 
Ramosetron 0.3 mg prior to 
induction 
Propofol: induced/maintained (target 
blood concentration 3.0-4.5mcg/ml) 
Remifentanil: induced/ maintained 
(target blood concentration 3.5-4.5 
ng/ml) 
 
Paralytic, reversal, pain med same 
for both groups: rocuronium 0.6 
m/kg 
Pyridostigmine 0.03 mg/kg 
Glycopyrrolate 0.002 mg/kg 




Headache: 16 (44.4%) 
Dizziness: 4 (11.1%) 
 
Sevoflurane Group: 
Headache: 15 (41.7%) 
Dizziness: 10 (27.8%) 
Limitations 
 








D-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol administered at the end of surgery in 
laparoscopic assisted vaginal hysterectomy. The Korean Society of Anesthesiologists, 66(3): 210-215.  
http://dx.doi.org/10.4097/kjae.2014.66.3.210 
Nausea & Vomiting 
 
Control Group (n=40) 
0-2h: 19 (47.5%) 
2-24h: 8 (20%) 
24-48h: 2 (5%) 
 
Propofol 0.5 Group 
(n=33) 
0-2h: 4 (12.1%) 
2-24h: 10 (30.3%) 
24-48h: 3 (7.5%) 
 
Propofol 1.0 Group 
(n=34) 
0-2h: 7 (20.6%) 
2-24h: 13 (38.2%) 





0-2h: 9 (22.5%) 
2-24h: 2 (5%) 
24-48h: 0 
 
Propofol 0.5 Group 
0-2h: 1 (3%) 
2-24h: 6 (18.1%) 
24-48h: 4 (11.7%) 
 
Propofol 1.0 Group 
0-2h: 2 (5.9%) 
2-24h: 7 (20.5%) 
















Delayed emergence time: 
Control Group:  
11.2 ± 3.8 minutes 
Propofol 0.5 Group: 
13.8 ± 5.1 minutes 
Propofol 1.0 Group: 
14.6 ± 6.5 minutes 
 
VAS Score: Post-operative 
pain and severity of nausea 
VAS >5, Vomiting >1, need 
for rescue anti-emetic in 
PACU 
 
Control Group:  
0-2h: 6.7 ± 1.8, 2-24h: 5.3 ± 
1.6, 24-48h: 1.6 ± 0.9 
 
Propofol 0.5 Group: 
0-2h: 6.4 ± 2.9, 2-24h: 4.9 ± 
2.1, 24-48h: 1.5 ± 1.2 
 
Propofol 1.0 Group: 
0-2h: 6.2 ± 2.9, 2-24h: 5.1 ± 














D-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015).  Prevention of postoperative nausea and vomiting with sub 
hypnotic dose of propofol in patients undergoing lower abdominal surgery: A prospective, randomized, double-blind study. 
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239 




Propofol 20mg Group:   
6 (23.1%) 











0.15mg/kg IV used 
 
Control Group: 
6 (23.1%), Mean dose: 
12 ± 4.6mg 
 
Propofol Group (G1): 
4 (15.2%), Mean dose: 
5.2 ± 2.1 mg 
 
Propofol Group (G2): 












Induction/ Maintenance Meds 
 
Induction: 






Isoflurane 1 MAC 
50% Nitrous Oxide & Oxygen 
Side Effects 
 
No side effects from 
the anti-emetics 




No other side effects 
noted in the study 
Limitations 
 
Small sample size, 
followed subjects 




D-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic dose of propofol on prevention of 
postoperative nausea and vomiting as part of multimodal antiemetic in patients undergoing open abdominal surgery: A prospective 
cohort study. International Journal of Surgery Open, 10(2018), 15-20. https://doi.org/10.1016/j.ijso.2017.11.008 
Nausea & Vomiting 
 
Propofol group: 
0-6h: 11 (30.6%) 
6-12h: 8 (22.2%) 
12-24h: 7 (19.4%) 
 
Control group: 
0-6h: 24 (66.7%) 
6-12h: 14 (38.9%) 











Reglan 10mg for 




0-6h: 5 (13.9%) 




0-6h: 15 (41.7%) 
6-12h: 5 (13.9%) 




Ketamine 2 mg/kg or thiopental 
sodium 5mg/kg, fentanyl 0.1mcg/kg  
 
Intubation: Suxamethonium 
Maintenance: vecuronium halothane  
with or without morphine  
 
Reversal:  
neostigmine 0.05mg/kg  



















Propofol: 6 (16.7%) 

















Critical Appraisal Skills Programme (CASP) Checklist 
Section A: Are the results of the review valid?               Yes     Can’t Tell     No 
1. Did the review address a clearly focused question? 
2. Did the authors look for the right type of papers?                         
3. Do you think all the important, relevant studies  
    were included? 
4. Did the review’s authors do enough to assess quality  
   of the included studies? 
5. If the results of the review have been combined,  
    was it reasonable to do so? 
Section B: What are the results?                                            
6. What are the overall results of the review?  
7. How precise are the results?   
Section C: Will the results help locally?                         Yes     Can’t Tell       No 
8. Can the results be applied to the local population?  
9. Were all important outcomes considered?  











                        Completed CASP Checklist 
F-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the 
antiemetic effect of midazolam following intragastric balloon insertion. Journal of 
Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/0970-
9185.137272 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused issue?    
 
 2. Was the assignment of patients to treatments   
    randomized?  
 
3. Were all the patients who entered the trial  
    properly accounted for at its conclusion? 
 
4. Were patients, health workers, and study                                       
     personnel “blind” to treatment?  
 
5. Were the groups similar at the start of the   
     trial?     
 
 6. Aside from the experimental intervention,  
     were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
   




Section C: Will the results help locally?   
 
 9. Can the results be applied in your context?    
  
 10. Were all clinically important outcomes    
        considered?  
 
 11. Are the benefits worth the harms and costs?                      
 
 
          YES 
 
           X 
              
           X 
 
              
          X 
 
              
X                                          
                                        
             
           X 
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          X 
           






















F-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat 
Erdem, A. (2014). Is infusion of sub hypnotic propofol as effective as dexamethasone in 
prevention of post-operative nausea and vomiting related to laparoscopic 
cholecystectomy? A randomized controlled trial. BioMed Research International, 2015, 
1-5.https://dx.doi.org/10.1155 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused   
    issue?   
   
2. Was the assignment of patients to    
    treatment randomized?  
 
3. Were all the patients who entered the trial  
     properly accounted for at its conclusion?  
 
 4. Were patients, health workers, and study  
personnel “blind” to treatment?  
 
 5. Were the groups similar at the start of the   
     trial?     
 
6. Aside from the experimental intervention,                                
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
 7. How large was the treatment effect?   
 
 8. How precise was the estimate of the  
    treatment  effect? 
 
 
Section C: Will the results help locally?   
 
 9. Can the results be applied in your  
    context?    
  
10. Were all clinically important outcomes   
       considered?  
 























































F-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect 
of midazolam and midazolam-dexamethasone on postoperative nausea and vomiting 
in elective middle ear surgery. Advanced Biomedical Research, 1(9), 1-9. 
http://doi:10.4103/2277-9175.96052 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused  
    issue?     
 
2. Was the assignment of patients to treatment  
    randomized?  
 
3. Were all the patients who entered the trial  
    properly accounted for at its conclusion?  
 
4. Were patients, health workers, and study  
    personnel “blind” to treatment?  
 
5. Were the groups similar at the start of the     
    trial?     
 
6. Aside from the experimental intervention,  
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
 
8. How precise was the estimate of the  






Section C: Will the results help locally?   
 
9. Can the results be applied in your context?     
 
10. Were all clinically important outcomes  
       considered?  
 
11. Are the benefits worth the harms and   
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        X                                  
 
       





























F-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic 
administration of haloperidol plus midazolam reduces postoperative nausea and vomiting 
better than using each drug alone in patients undergoing middle ear surgery. Saudi Journal 
of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028 
Section A: Are the results of the trial valid? 
       
 1. Did the trial address a clearly focused issue?  
    
 2. Was the assignment of patients to treatments 
randomized?  
 
 3. Were all the patients who entered the trial  
     properly accounted for at its conclusion?  
 
 4. Were patients, health workers, and study  
      personnel “blind” to treatment?  
 
5. Were the groups similar at the start of the  
     trial?     
 
6. Aside from the experimental intervention,  
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
 
8. How precise was the estimate of the  






Section C: Will the results help locally?   
 
9. Can the results be applied in your context?     
 
10. Were all clinically important outcomes  
      considered?  
 
11. Are the benefits worth the harms and costs?     
 
          YES 
 
            X  
             
            X 
 
             
           X 
             
              
           X 
 
             
           X 
              
 










more than Haldol 
alone, but combo 
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      X               
 
      

























F-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S. 
Y. (2016). Effect of total intravenous anesthesia and prophylactic ramosetron on 
postoperative nausea and vomiting after thyroidectomy: A prospective, randomized 
controlled study. Journal of International Medical Research, 44(1), 81–88. 
https://doi.org/10.1177/0300060515607384 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused issue?  
    
2. Was the assignment of patients to treatments 
    randomized?  
 
 3. Were all the patients who entered the trial  
properly accounted for at its conclusion?  
 
 4. Were patients, health workers, and study  
personnel “blind” to treatment? 
 
5. Were the groups similar at the start of the  
     trial?     
 
6. Aside from the experimental intervention,     
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
 
8. How precise was the estimate of the  




Section C: Will the results help locally?   
 
 9. Can the results be applied in your context?     
       
10. Were all clinically important outcomes  
      considered?  
       

































        
        X 
       
        X 
  
         






F-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol 
administered at the end of surgery in laparoscopic assisted vaginal hysterectomy. The 
Korean Society of Anesthesiologists, 66(3): 210-215. 
http://dx.doi.org/10.4097/kjae.2014.66.3.210 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused issue?  
    
2. Was the assignment of patients to treatments             
     randomized?  
 
3. Were all the patients who entered the trial  
     properly accounted for at its conclusion?  
 
4. Were patients, health workers, and study  
     personnel “blind” to treatment?  
 
5. Were the groups similar at the start of the trial?     
 
6. Aside from the experimental intervention,  
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
 
8. How precise was the estimate of the  
    treatment effect? 
 
 
Section C: Will the results help locally?   
 
9. Can the results be applied in your context?     
       
10. Were all clinically important outcomes  
       considered?  
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         X 
            
      X 
 
            
        X 
 
            
        X 
 
          
       X 
            











to control group 
 
       
     X 
          
     X 
 
          









F-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015).  Prevention of 
postoperative nausea and vomiting with sub hypnotic dose of propofol in patients 
undergoing lower abdominal surgery: A prospective, randomized, double-blind study. 
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239 
Section A: Are the results of the trial valid? 
       
1. Did the trial address a clearly focused issue?     
       
2. Was the assignment of patients to treatments 
    randomized?  
       
3. Were all the patients who entered the trial  
   properly accounted for at its conclusion?  
       
4. Were patients, health workers, and study  
    personnel “blind” to treatment?  
  
5. Were the groups similar at the start of the   
    trial?     
  
6. Aside from the experimental intervention,  
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
7. How large was the treatment effect?   
   
8. How precise was the estimate of the  
    treatment effect? 
 
 
Section C: Will the results help locally?   
 
 9. Can the results be applied in your context?     
       
10. Were all clinically important outcomes  
       considered?  
       














































F-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic 
dose of propofol on prevention of postoperative nausea and vomiting as part of 
multimodal antiemetic in patients undergoing open abdominal surgery: A prospective 
cohort study. International Journal of Surgery Open, 10(2018), 15-20. 
https://doi.org/10.1016/j.ijso.2017.11.008 
Section A: Are the results of the trial valid? 
             
1. Did the trial address a clearly focused  
     issue?  
    
2. Was the assignment of patients to  
     treatments  randomized?  
 
3. Were all the patients who entered the trial  
     properly accounted for at its conclusion?  
     
 4. Were patients, health workers, and study  
      personnel “blind” to treatment?  
      
5. Were the groups similar at the start of the  
     trial?     
      
6. Aside from the experimental intervention,  
    were the groups treated equally?  
    
 
 Section B: What are the results?  
   
 7. How large was the treatment effect?                                  
   
8. How precise was the estimate of the  
    treatment effect?                                                                         
                                                                                                            
                                                  
      
Section C: Will the results help locally?   
 
9. Can the results be applied in your context?                    
       
10. Were all clinically important outcomes  
      considered?                                                                      
       
 11. Are the benefits worth the harms and  
      costs?                                                                        
 
             YES   
 
               X  
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               X 
 
    
              X 
   
 








 Propofol group less   
incidence of PONV 
& less rescue anti-
emetic for severe 
nausea 
     
  
 





   X  
CAN’T     
  TELL 
 
        
 






































      




    
     
     3 
 







      4 
 
 
Significant reduction in severity of 
PONV in ondansetron/ midazolam 
group using N/V scores, No 
significant reduction of incidence of 
PONV 
 
Significant reduction in PONV in 
propofol and dexamethasone group 




Reduced mean nausea score & 
reduced vomiting frequency in 
midazolam/ dexamethasone group 
Midazolam alone reduced PONV 
more than Haldol alone, 




Significant reduction in propofol 
group 
 
No mention of rescue anti-





0-6h: Group D & P comparable, 
both reduced compared to 
control 
6-12h: Group D superior to 
Group P 
12-24h: no significant 
differences among groups 
 










Significant mild sedation in both 
groups, significant moderate 




No significant difference in 





Longer recovery times in PACU 
related to more vomiting episodes 




































   
     5 
 
 
     
      
     6 
 
      
 
 
      





     8 
 
Significant reduction in propofol 




Reduced PONV in propofol groups 
compared to control, Propofol 30mg 





Significant reduction in PONV in 




Significant reduction in PONV in 







Midazolam group(M) required 
less than Haldol group (H), MH 
group required less than M 
group 
 
Significant reduction in PONV 




Significantly less in both 
propofol groups compared to 




Significant less requirement for 





Significant less requirement for 
propofol group compared to 
control group 
 
No significant adverse effects 




Time to extubation significantly 










No significant adverse effects 
noted 
morphine 









PCA end  
of case 
 
 
 
Fentanyl at 
induction 
Morphine 
 
 
Fentanyl at 
induction 
Morphine 
for 
intubation 
 
29 
 
 
